Research programme: antibody drug conjugates - Vincerx Pharma
Latest Information Update: 19 May 2024
At a glance
- Originator Vincerx Pharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 19 May 2024 Early research in Solid tumours in USA (Parenteral), prior to May 2024 (Vincerx Pharma pipeline, May 2024)